Increased Tolerance to Endotoxin by Granulocyte-Macrophage Colony-Stimulating Factor-Deficient Mice

Journal of Immunology

Volumn 159, Issue 3, 1997, Pages 1412-1417

  Basu, Sunanda ^a   Dunn, Ashley R ^a   Marino, Michael W ^a,b   Savoia, Helen ^a   Hodgson, George ^a   Lieschke, Graham J ^a   Cebon, Jonathan ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIPOPOLYSACCHARIDE; NITRIC OXIDE;

ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; C57BL MOUSE; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INNATE IMMUNITY; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MOUSE; MOUSE MUTANT; SEPTIC SHOCK;

ANIMALS; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNE TOLERANCE; IMMUNITY, NATURAL; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; SHOCK, SEPTIC;

EID: 0031201475     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Gasson, J. C., R. H. Weisbart, S. E. Kaufman, S. C. Clark, R. M. Hewick, G. G. Wong, and D. W. Golde. 1984. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science 226:1339.
2. Horiguchi, J., M. K. Warren, and D. Kufe. 1987. Expression of the macrophage specific colony-stimulating factor in human monocytes treated with granulocyte-macrophage colony-stimulating factor. Blood 69:1259.
3. Burgess, A. W., and D. Metcalf. 1980. The nature and action of granulocyte-macrophage colony stimulating factors. Blood 56:947.
4. Gough, N. M., and N. A. Nicola. 1990. Granulocyte-macrophage colony-stimulating factor. In Colony-Slimulating Factors: Molecular and Cellular Biology. T. M. Dexter, J. M. Garland, and N. G. Testa, eds. Marcel Dekker, New York, p. 111.
5. Antman, K. S., J. D. Griffin, and A. Elias. 1988. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Engl. J. Med. 319:593.
6. Brandt, S. P., W. P. Peters, and S. K. Atwater. 1988. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on haematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 319:869.
7. Lieschke, G. J., and A. W. Burgess. 1992. Granulocyte-macrophage colony-stimulating factor. N. Engl. J. Med. 327:28.
8. Weisbart, R. H., D. W. Golde, C. C. Clark, G. G. Wong, and J. C. Gasson. 1985. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 314:361.
9. Lopez A. F., J. Williamson, J. R. Gamble, C. G. Begley, J. M. Harlan, A. Klabanoff, A. Waltersdorph, G. Wong, S. C. Clark, and M. A. Vadas. 1986. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression and survival. J. Clin. Invest. 78:1220.
10. Aranout, M. A., E. A. Wang, S. C. Clark, and C. A. Sieff. 1986. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J. Clin. Invest. 78:597.
11. Fischer, H. G., S. Frosch, K. Reske, and A. B. Reske-Kunz. 1988. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augment antigen presentation function. J. Immunol. 141:3882.
12. Freund, M., and H.-D. Kleine. 1992. The role of GM-CSF in infection. Infection 20:S48.
13. Cicco, N. A., A. Lindemann, J. Contentea, A. Vandenbussche, M. Lubbert, J. Gauss, R. Mertesmann, and F. Herrman. 1990. Inducible production of IL-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α. Blood 75:2049.
14. Sisson, S. D., and C. A. Dinarello. 1988. Production of interleukin-1 α and interleukin-1 β and tumor necrosis factor by human peripheral blood mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood 72:1368.
15. Heidenreich, S., J. H. Gong, A. Schmidt, M. Nain, and D. Gemsa. 1989. Macrophage activation by granulocyte/macrophage colony-stimulating factor. J. Immunol. 143:1189.
16. Brissette, W. H., D. A. Baker, E. J. Stam, J. P. Umland, and R. J. Griffiths. 1995. GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF. Cytokine 7:291.
17. Gorgen, I., T. Hartung, M. Leist, M. Niehorster, G. Tiegs, S. Uhlig, F. Weitzel, and A. Wendel. 1992. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor. J. Immunol. 149:918.
18. Tiegs, G., J. Barsig, B. Matiba, S. Uhlig, and A. Wendel. 1994. Potentiation by granulocyte macrophage colony-stimulating factor of lipopolysaccharide toxicity in mice. J. Clin. Invest. 93:2616.
19. Stanley, E., G. J. Lieschke, D. Grail, D. Metcalf, G. Hodgson, J. A. Gall, D. W. Maher, J. Cebon, V. Sinickas, and A. R. Dunn. 1994. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc. Natl. Acad. Sci. USA 91:5592.
20. Van Snick, J., S. Cayphas, A. Vink, C. Clyttenhove, P. G. Coulie, M. R. Rubira, and R. J. Simpson. 1986. Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. USA 83:9679.
21. Granger, D. L., J. B. J. Hibbs, J. R. Perfect, and D. T. Durack. 1992. Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J. Clin. Invest. 89:867.
22. Dinarello, C. A. 1996. Interleukin-1 and its biologically related cytokines. Adv. Immunol. 44:153.
23. Okusawa, S., J. A. Gelfand, T. Ikejama, R. J. Connolly, and C. A. Dinarello. 1988. Interleukin-1 induced shock like state in rabbits. J. Clin. Invest. 81:1162.
24. Starnes, F. H. J., M. K. Pearce, A. Tewari, J. H. Tewari, J. H. Yim, J. C. Zou, and J. S. Abrams. 1990. Anti-IL-6 monoclonal antibodies protect against lethal E. coli infection and lethal tumor necrosis factor-α challenge in mice. J. Immunol. 145: 4185.
25. Adreka, D., J. Le, and J. Vilcek. 1989. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143:3517.
26. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Stelnmetz, and H. Bluethmann. 1993. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-α mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364:798.
27. Heremans, H., J. Van Damme, C. Dillen, R. Dijkmans, and A. Billan. 1990. Interferon-γ, a mediator of lethal lipopolysaccharide-induced Schwartzman-like shock reactions in mice. J. Exp. Med. 171:1853.
28. Heinzel, F. P. 1990. The role of IFN-γ in the pathology of experimental endotoxemia. J. Immunol. 145:2920.
29. Doherty, G. M., J. R. Lange, H. M. Langstein, H. R. Alexander, C. M. Buresh, and J. A. Norton. 1992. Evidence for interferon-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J. Immunol. 149:1666.
30. Car, B. D., V. M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Agnet, and B. Ryffel. 1994. Interferon γ receptor deficient mice are resistant to endotoxin shock. J. Exp. Med. 179:1437.
31. Billau, A., H. Heremans, F. Vandekerckhove, and C. Dillen. 1987. Anti-interferon-γ antibody protects mice against the generalized Schwartzmann reaction. Eur. J. Immunol. 17:1851.
32. Cicco, N. A., A. Lindemann, J. Contentea, A. Vandenbussche, M. Lubbert, J. Gauss, R. Mertesmann, and F. Herrmann. 1990. Inducible production of IL-6 by human polymorphonuclear neutrophils: role of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α. Blood 75:2049.
33. Toda, H., A. Maruta, Y. Oka, K. Uda, N. Tanaka, I. Ohashi, T Mori, and N. Matsuura. 1994. Effect of granulocyte-macrophage colony-stimulating factor on sepsis induced organ injury in rats. Blood 83:2893.
34. Aldridge, S. 1993. Meeting the challenge of sepsis. Trends Biotechnol. 11:37.
35. Beutler, B., and A. Cerami. 1987. Cachectin: more than a tumor necrosis factor. N. Engl. J. Med. 316:379.
36. Bauss, F., W. Dorge, and D. A Mannel. 1987. Tumor necrosis factor mediates endotoxic effects in mice. Infect. Immun. 55:1622.
37. Tracey, K. J., B. Beutler, S. F. Lowry, J. Merryweather, S. Wolpe, I. W. Milsark, R. J. Hirari, T. J. Fahey, A. Zentella, J. D. Albert, G. T. Shiris, and A. Cerami. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234:470.
38. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1996. Anticachectin/TNF monoclonal antibodies prevent septic shock during bacteraemia. Nature 330:662.
39. Waage, A., P. Brandtzaeg, A. Halstensen, P. Kierulf, and T. Espevik. 1989. The complex pattern of cytokines in serum from patients with meningococcal septis shock: association between interleukin-6, interleukin-1, and fatal outcome. J. Exp. Med. 169:333.
40. Waage, A., and T. Espevick. 1988. Interleukin-1 potentiates the lethal effect of tumor necrosis factor-α/cachectin in mice. J. Exp. Med. 161:1987.
41. Everaedrt, B., P. Brouckaert, A. Shaw, and W. Fiers. 1989. Four different interleukin-1 species sensitize to the lethal action of tumor necrosis factor. Biochem. Biophys. Res. Commun. 163:378.
42. Hack, C. E., E. R. de Groot, R. J. F. Felt-Bersma, J. H. Nuijens, R. J. M. Strack van Schijndel, A. J. M. Eerenberg-Belmer, L. G. Thijs, and L. A. Aarden. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704.
43. VanBadel, S., C. Libert, and W. Fiers. 1991. Interleukin-6 enhances the expression of tumor necrosis factor on hepatoma cells and hepatocytes. Cytokine 3:149.
44. Cairns, J. A., G. R. Guy, and Y. H. Tan. 1992. Interleukin-6 regulates the cytotoxic effects of tumor necrosis factor on U937 cells. Immunology 75:669.
45. Laubach, V. E., E. G. Shesely, O. Smithies, and P. A. Sherman. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA 92:10688.
46. Gomez-Jimenez, J., A. Salgado, M. Mourelle, M. C. Martin, R. M. Segura, R. Peracaula, and S. Moncada. 1995. L-arginine: nitric oxide pathway in endotoxemia and septic shock. Crit. Care Med. 23:253.
47. Campbell, I. L., A. Samimi, and C. S. Chiang. 1994. Expression of the inducible nitric oxide synthase: correlation with neuropathology and clinical features in mice with lymphocytic choriomeningitis. J. Immunol. 153:3622.